Premium: Of Sun Pharma, Infy and Some Results That Spooked The Day
Sunpharma is down 13% today after announcing that things after the Ranbaxy acquisition aren’t exactly rosy. They had a conference call yesterday in ...
Like our content? Join Capitalmind Premium.
- Equity, fixed income, macro and personal finance research
- Model equity and fixed-income portfolios
- Exclusive apps, tutorials, and member community
Subscribe Now
Or start with a free-trial
Already a subscriber?
Login Now
Related Posts
Taking Stock: A Deeper Look at Aarti Industries
Over the last decade, the Indian chemical industry has distinguished itself as a global leader in terms of growth and creating shareholder value. The chemical ...
Why we are buying: Capitalmind Focused Factsheet June 2022
After the recent market correction, we believe the time has come to move from being cautious to being (a little) greedy. We've exited some fundamentally weak ...
A Look at the PLI Scheme and Sectors Impacted
The government announced Production Linked Incentive (PLI) scheme this month, this was in addition to the same scheme announced earlier this year. PLI scheme ...